Understand BHOCBHOC - What It Really Is.Why It Exists.→
BHOC NETWORKScientific Evidence Hub ↗BHOC Veterinary bhocvet.comBHOC Transplant coming soon

Historical source note · 2005 agreement · Published 2026

The 2005 Navy–Biopure agreement: what 1,500 units and $650 actually meant

Amendment #3 to a Naval Medical Research Center and Biopure research agreement describes a conditional HBOC-201 defense contingency provision. The figure is a cost ceiling in the agreement, not evidence of an actual Navy purchase at that price.

Historical record: 2005Primary source: SEC exhibit
BHOC editorial text graphic: U.S. Navy Naval Medical Research Center and Biopure RESUS CRADA Amendment #3, 2005; conditional HBOC-201 provision
BHOC editorial source graphic. Plain text only; no U.S. Navy insignia, official logo or endorsement.
2005Amendment #3 signed by the Navy on 29 June and Biopure on 30 September.
1,500HBOC-201 units specified for a defense contingency involving military unit(s) totaling at least 10,000 personnel.
≤ $650Per-unit ceiling on Biopure’s estimated total costs at the time of a written NMRC request.

What the document provided

Under Section 10.5.1 of the RESUS cooperative research and development agreement amendment, a defined military need and a written request from the Naval Medical Research Center (NMRC) would trigger Biopure’s good-faith effort to provide HBOC-201. That effort remained subject to realistic production and distribution capacity, federal procurement procedures and applicable law. The provision described contingency resuscitation when blood transfusion was unavailable.

The $650 figure covered Biopure’s estimated manufacturing, regulatory, administrative and distribution costs per unit at the time of such a request. It was a ceiling for that conditional provision. The amendment’s separate Section 10.5.2 addressed possible U.S. government sales using different pricing terms.

What this record does not establish: It does not document a written request, an order for 1,500 units, delivery to military personnel, patient use, or an actual $650 Navy purchase price. It does not constitute a current U.S. Navy or FDA approval of BHOC Therapeutics or its products.

Read the underlying record

The full 2005 amendment is reproduced as an exhibit in a Biopure filing with the U.S. Securities and Exchange Commission. The linked BHOC historical page places this clause alongside the broader Navy research chronology and keeps research purchases separate from this contingency provision.

SEC filing: RESUS CRADA and Amendment #3 ↗BHOC historical source chronology ↗

Source location: Amendment #3, Article 10.5, Sections 10.5.1–10.5.2; signature page. This note was published in 2026 about a 2005 record. The editorial graphic is not a U.S. government image.